Emgality (galcanezumab) Letter of Medical Necessity
Emgality (galcanezumab) is approved for both migraine and episodic cluster headache prevention. PA documentation differs by indication.
FDA-Approved Indications
- ● migraine prevention in adults
- ● episodic cluster headache
Why Emgality Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Headache diary missing
- 2. Cluster headache phase not documented
- 3. Two preventives not tried
What to Include in a Emgality Letter of Medical Necessity
Document indication, headache frequency and severity, prior preventives, and any features specific to cluster vs migraine.
Key clinical evidence to cite:
- ✓ EVOLVE-1, EVOLVE-2, REGAIN, CONQUER, GALCANE-Cluster
Relevant guidelines:
- 📖 AHS Position Statement
Emgality Prior Authorization Criteria
Standard criteria across major US payers for Emgality. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Emgality
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Emgality Prior Authorization FAQ
Why was my Emgality prior authorization denied?
The most common denial reasons for Emgality are: Headache diary missing; Cluster headache phase not documented; Two preventives not tried.
What should a Emgality Letter of Medical Necessity include?
Document indication, headache frequency and severity, prior preventives, and any features specific to cluster vs migraine.
Which payers cover Emgality?
Emgality is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, though formulary tier and prior authorization criteria vary.